PHOTOSYNTHESIS AND ANATOMY STRUCTURE OF TEA TREE LEAVES UNDER DIFFERENT INTERCROPPING PATTERNS



Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer

The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment.The study sought to assess the cost-effectiveness of T-DXd in b

read more